Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. Company
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AVROBIO, Inc.
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with a lentiviral vector to insert a functional copy of the gene that is defective in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of six lentiviral-based gene therapy programs, which includes AVR-RD-01 for the treatment of Fabry disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-06 for the treatment of Gaucher disease type 3; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Managers
Name Title Age Since
Geoff MacKay President, Chief Executive Officer & Director 54 2015
Erik Ostrowski Chief Financial Officer & Treasurer 48 -
Christopher Mason, Dr. Chief Scientific Officer 63 2015
Kim Raineri Chief Manufacturing & Technology Officer - 2020
Essra Ridha, Dr. Chief Medical Officer - 2021
Christopher Paige, Dr. Independent Director 68 2016
Bruce Lee Booth, Dr. Chairman 47 2016
Ian T. Clark Independent Director 60 2018
Annalisa Mary Jenkins, Dr. Independent Director 55 2018
Philip B. Donenberg Independent Director 60 2018
Members of the board
Name Title Age Since
Bruce Lee Booth, Dr. Chairman 47 2016
Geoff MacKay President, Chief Executive Officer & Director 54 2015
Christopher Paige, Dr. Independent Director 68 2016
Ian T. Clark Independent Director 60 2018
Annalisa Mary Jenkins, Dr. Independent Director 55 2018
Philip B. Donenberg Independent Director 60 2018
Philip J. Vickers, Dr. Independent Director 61 2019
Gail M. Farfel, Dr. Director 57 2020
Shareholders
NameEquities%
Atlas Venture, Inc. 4,541,381 10.4%
Camber Capital Management LP 3,133,333 7.18%
JPMorgan Investment Management, Inc. 2,787,775 6.39%
Federated Global Investment Management Corp. 2,388,000 5.47%
Deep Track Capital LP 2,211,129 5.07%
GMT Capital Corp. 2,133,214 4.89%
JPMorgan Asset Management (UK) Ltd. 1,736,506 3.98%
The Vanguard Group, Inc. 1,657,259 3.80%
Clarus Ventures LLC 1,481,162 3.40%
Eventide Asset Management LLC 1,305,307 2.99%
Company contact information
Avrobio, Inc.
One Kendall Square
Building 300
Suite 201
Cambridge, MA 02139

Phone : +1.617.914.8420
Web : http://www.avrobio.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of AVROBIO, Inc.
Sector Bio Therapeutic Drugs